Advert - AstraZeneca – Case AUTH/3729/1/23

• Date posted
  17 February 2025
• Sanction
  Advertisement,
• Case number/s
  AUTH/3729/1/23 - Complainant/s v AstraZeneca

For promoting capivasertib on LinkedIn prior to the grant of its marketing authorisation, in a post that contained the strong phrase ‘remarkable benefits’, and the impression created by very senior staff acting contrary to the company’s global social media policy, AstraZeneca was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1 - Promoting a medicine prior to the grant of the marketing authorisation

Clause 5.1 - Failing to maintain high standards